Ascendis Pharma A (ASND) Liabilities and Shareholders Equity (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $2.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 110.06% year-over-year to $2.3 billion; the trailing twelve-month figure through Mar 2026 stood at $6.4 billion (down 0.8% YoY), and the FY2025 full-year result was $1.5 billion, down 55.46% from the prior year.
• Liabilities and Shareholders Equity rose to $2.3 billion in Q1 2026, from $1.5 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.4 billion in Q4 2024 to a low of $816.6 million in Q2 2024.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 278.36% in 2024 and slumped 54.89% in 2025, its largest moves.
• Tracing ASND's Liabilities and Shareholders Equity over 5 years: stood at $1.1 billion in 2022, then fell by 20.1% to $888.3 million in 2023, then jumped by 278.36% to $3.4 billion in 2024, then tumbled by 54.89% to $1.5 billion in 2025, then jumped by 54.68% to $2.3 billion in 2026.
• Business Quant data shows ASND's Liabilities and Shareholders Equity at $2.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.